ANI PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ANI PHARMACEUTICALS, INC. | |
|---|---|
| By: | /s/ Nikhil Lalwani |
| Nikhil Lalwani | |
| President and Chief Executive Officer | |
| (principal executive officer) | |
| By: | /s/ Stephen P. Carey |
|---|---|
| Stephen P. Carey | |
| Senior Vice President, Finance and | |
| Chief Financial Officer | |
| (principal financial and accounting officer) |
Pursuant to the requirements the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Capacity | Date |
|---|---|---|
| /s/ Nikhil Lalwani | Director, President, andChief Executive Officer(principal executive officer) | February 29, 2024 |
| Nikhil Lalwani | ||
| /s/ Stephen P. Carey | Senior Vice President, Finance andChief Financial Officer(principal financial and accounting officer) | February 29, 2024 |
| Stephen P. Carey | ||
| /s/ Muthusamy Shanmugam | Director, Head of Research and Development and Chief Operating Officer of New Jersey Operations | February 29, 2024 |
| Muthusamy Shanmugam | ||
| /s/ Patrick D. Walsh | Director and Chairman of the Board ofDirectors | February 29, 2024 |
| Patrick D. Walsh | ||
| /s/ Thomas J. Haughey | Director | February 29, 2024 |
| Thomas J. Haughey | ||
| /s/ David B. Nash, M.D., M.B.A. | Director | February 29, 2024 |
| David B. Nash, M.D., M.B.A. | ||
| /s/ Matthew J. Leonard | Director | February 29, 2024 |
| Matthew J. Leonard | ||
| /s/ Jeanne Thoma | Director | February 29, 2024 |
| Jeanne Thoma | ||
| /s/ Antonio Pera | Director | February 29, 2024 |
| Antonio Pera | ||
| /s/ Renee Tannenbaum | Director | February 29, 2024 |
| Renee Tannenbaum | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.